Key Highlights
- Artelo Biosciences (ARTL) shares climbed over 40% during pre-market hours on March 18, 2026
- The rally followed news of a fully-funded clinical trial partnership with Belfast Health and Social Care Trust
- The research will evaluate ART27.13, a peripherally selective synthetic cannabinoid, in glaucoma and ocular hypertension patients
- Financial support comes from Glaucoma UK and the HSC R&D Division, with patient recruitment beginning Q2 2026
- This development follows a recent 1-for-3 reverse stock split implemented on March 10, 2026
Shares of Artelo Biosciences (ARTL) rocketed more than 40% during Wednesday’s pre-market session following the company’s disclosure of a fully-funded clinical research project examining its cannabinoid compound ART27.13 for glaucoma treatment.
Artelo Biosciences, Inc., ARTL
The investigator-led research initiative was established through a partnership with Belfast Health and Social Care Trust (BHSCT). Financial backing is being delivered by Glaucoma UK alongside the HSC R&D Division.
The research design follows a pilot, randomized, cross-over format. Investigators will examine ART27.13’s ability to reduce intraocular pressure (IOP) in individuals diagnosed with glaucoma or ocular hypertension.
ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This mechanism allows it to engage cannabinoid receptors located in peripheral tissues—such as ocular structures—while avoiding central nervous system activation.
Current glaucoma therapies predominantly rely on topical eye drop formulations, which often face challenges regarding patient compliance and sustained efficacy. According to Artelo, ART27.13’s molecular architecture may circumvent the psychoactive adverse effects that have historically constrained cannabinoid-based ophthalmic interventions.
Regulatory clearance for the trial protocol has been secured from both an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Initial patient recruitment is anticipated during Q2 2026.
Professor Augusto Azuara-Blanco, a clinical professor specializing in ophthalmology at Queen’s University Belfast and a distinguished authority in glaucoma investigation, will serve as the principal investigator.
Glaucoma impacts over 80 million individuals globally and represents a primary cause of permanent vision loss. Increased IOP stands as the principal modifiable risk element in disease advancement.
Artelo’s Cost-Effective Development Approach
CEO Greg Gorgas characterized the arrangement as aligned with the company’s broader capital-preservation development philosophy. The organization is enabling third-party sponsors to execute this investigation while maintaining internal resources concentrated on ART27.13’s core indication—cancer-associated anorexia.
“This collaboration exemplifies our capital-efficient development strategy,” Gorgas said in the announcement. “Each study contributes to a growing body of evidence that could enhance the value of ART27.13.”
Under the partnership terms, Artelo will provide ART27.13 capsules as the Investigational Medicinal Product for the research protocol. Beyond this contribution, the economic responsibility rests with the trial’s independent funding sources.
Current Financial Position
The pre-market rally unfolds amid a difficult financial landscape. Artelo disclosed a net loss of $12.9 million for the fiscal year concluded December 31, 2025, representing an increase from the $9.8 million deficit recorded in the prior year.
Cash reserves and investment holdings totaled merely $0.6 million at that reporting date. InvestingPro’s Financial Health Score classifies the company’s position as “WEAK.”
On March 10, 2026, the organization executed a 1-for-3 reverse stock split. Outstanding common stock decreased from roughly 2.1 million shares to 708,323 shares after the consolidation.
Before Wednesday’s movement, ARTL had experienced a 67% decline across the preceding six-month period. The equity was exchanging hands at $4.85 with a market capitalization of approximately $3.47 million prior to the pre-market surge.
The glaucoma research initiative marks Artelo’s inaugural venture into ophthalmological applications and its first externally-sponsored clinical collaboration.
